Search

Displaying results 5291 - 5300 of 7604 in total
  1. Drug

    Eberconazole

    go.drugbank.com/drugs/DB13656
    Investigational

    Eberconazole is a broad-spectrum imidazole derivative.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  2. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

  3. Drug

    Tomuzotuximab

    go.drugbank.com/drugs/DB15178
    Investigational

    Tomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).

  4. Drug

    PT-2385

    go.drugbank.com/drugs/DB16055
    Investigational

    PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).

  5. Drug

    OS2966

    go.drugbank.com/drugs/DB17207
    Investigational

    OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]

  6. Drug

    AUM-601

    go.drugbank.com/drugs/DB17382
    Experimental

    It is currently being investigated in clinical trials for the treatment of cancer.

  7. Drug

    F6-734

    go.drugbank.com/drugs/DB17444
    Experimental

    F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine pentaacetic acid (DTPA) (hMN-14 × m734).[A255217,A255222]

  8. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  9. Drug

    CB-010

    go.drugbank.com/drugs/DB17711
    Investigational

    It is being investigated for the treatment of follicular lymphoma.[L46158]

  10. Drug

    NDX-3315

    go.drugbank.com/drugs/DB18671
    Investigational

    NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].